Alternative to allopurinol and febuxostat

See more Background Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol. According to American College of Rheumatology guidelines, allopurinol is the preferred first-line urate-lowering agent (NEJM JW Gen Med Jul 1 2020 and Arthritis

2024-03-28
    Betamethasone + dexchlorpheniramine maleate syrup
  1. Cardiovascular risk is increased in patients with gout
  2. The third control group was
  3. Conclusions
  4. Keywords: febuxostat, side effects, interactions
  5. The starting dose is 50 mg daily